7 mars 2023

Published Date: 10 Mar 2023

Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...

Read Full News

Latest News

DOACs Benefit AF Patients With Intermediate Stroke Risk

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an apparent increase in major bleeding.

Heart Failure Drug May Not Improve Exercise Fitness in nHCM

A heart failure drug combination may not improve exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy but is associated with favorable cardiac structural remodeling.

Mounjaro FDA-Approved to Reduce Cardiovascular Risk in T2D

Lilly's Mounjaro (tirzepatide) is now approved to reduce cardiovascular risk in adults with type 2 diabetes.

Weight Down, Steps Down: The GLP-1 Catch

Studies suggest that strong recommendations for exercise with GLP-1s are commonly not heeded; possible reasons vary.

Ginseng, the ‘Miracle Root’: How Strong Is the Evidence?

Evidence varies across ginseng uses, with some potential benefits but limited support for treating fatigue, cognitive decline, infections, diabetes, or cardiovascular disease.

Inpatient Weight Loss May Cut HF Rehospitalization Risk

Losing weight during hospitalization for heart failure in patients treated with intravenous loop diuretics is associated with a reduced 30-day risk for rehospitalization.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an apparent increase in major bleeding.

A heart failure drug combination may not improve exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy but is associated with favorable cardiac structural remodeling.

Lilly's Mounjaro (tirzepatide) is now approved to reduce cardiovascular risk in adults with type 2 diabetes.

Studies suggest that strong recommendations for exercise with GLP-1s are commonly not heeded; possible reasons vary.

Evidence varies across ginseng uses, with some potential benefits but limited support for treating fatigue, cognitive decline, infections, diabetes, or cardiovascular disease.

Losing weight during hospitalization for heart failure in patients treated with intravenous loop diuretics is associated with a reduced 30-day risk for rehospitalization.

News All Time

Vutrisiran May Stabilize Right Ventricle Function in ATTR-CM

Right ventricular dysfunction is linked to worse outcomes in patients with transthyretin amyloidosis with cardiomyopathy; vutrisiran treatment may help stabilize right ventricular function.

Inhaling Cannabis Tied to Less Cardiac Ectopy in Adults

Adults without a history of cardiac arrhythmias have less cardiac ectopy on days they were randomly assigned to inhale cannabis than on days they abstained.

Mildly Elevated Ketones May Protect Kidneys in T2D

In patients with type 2 diabetes, mildly elevated blood ketone body levels are associated with a lower risk of developing kidney complications, a study finds.

Common ASM Tied to Twofold Thromboembolic Risk With DOACs

Levetiracetam has been linked to an increased thromboembolic risk among adults with epilepsy receiving DOACs, but experts caution that, at this point, the finding is not practice-changing.

An Accordion’s Unlikely Assist in Heart Research

Researchers applied the physics of the instrument to a new device that reproduces the heart’s complex blood flow waveforms.

Mushrooms Gain Ground in Medicine Despite Limited Evidence

Mushroom compounds show potential across cancer, metabolic, and neurologic research, but most evidence remains preclinical and larger clinical trials are still needed.

Doctors Need Friends Outside Medicine, and It’s Not Easy

Doctors may find their closest friends in medicine and have little time for others. But experts say friendships outside the medical bubble matter more than ever.

Cardioprotection Rarely Used in Adults With Blood Cancers

Few adults on anthracycline chemotherapy for hematologic cancers receive strategies to protect their hearts.

Breakthrough Stroke in AF Linked to Drug Interactions

Patients who experience ischemic stroke despite ongoing oral anticoagulation for atrial fibrillation often have identifiable causes such as drug interactions or non-cardioembolic disease.

Medicine on Screen: 10 Films Doctors May Want to Rewatch

From Alzheimer’s to pandemics, these films show how medicine is lived as much as it is practiced.

Sequential or Simultaneous Therapy in Chronic Kidney Disease

Experts debate the pros and cons of stepwise vs simultaneous therapy for chronic kidney disease in an era of multifactorial treatment choices.

Deep Dive: DPP-4 Inhibitors After the ADA Downgrade

ADA now says limit or discontinue gliptins. Cardiologist Benjamin Scirica, MD, on why sitagliptin still looks safest of the four.

New Tool May Identify Adverse Events in Hospitalized Kids

A new trigger tool can help identify adverse events in hospitalized children, showing good reviewer agreement and aiding the systematic detection of patient harm.

Central Obesity Reveals Hidden Risk in Overweight

Adding waist-based central obesity measures to BMI may improve the identification of risk for multimorbidity in adults with BMI-defined overweight.

Canada Joins Global Call for Exercise Physiology for Obesity

A new joint global statement says that exercise physiologists should be part of a multidisciplinary obesity care team for patients taking weight management medications.

Fitness Changes Over Time Linked to Cardiovascular Risk

In adults, changes in cardiorespiratory fitness over time — not just a single measurement — are linked to their risks for cardiovascular disease and death.

Recommended News For You

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

Novel Psychedelic Promising on Resistant Depression

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

New imaging guidelines for head and neck cancers, a step toward practice change

Recommended Articles For You

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care? 

Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Independent Risk Factors for "Deaths of Despair" Found.

2.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

3.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

4.

Infection Burden High With Myeloma T-Cell Therapies

5.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

1.

Genomic Control of Erythropoietic Stem Cell Renewal

2.

Case-Based Learning on Unexpected Cytopenia Patterns Following Advanced Therapies

3.

Subchorionic Hematoma: Causes, Symptoms, and Treatment 

4.

Clonal Hematopoiesis as a Mechanism of Age-Related Disease

5.

Transformative Insights in Oncology in Daily Practice

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Innovations in Hematology

2.

Case-Based Learning: Oncology

3.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

5.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot